Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
P84022 |
SMAD3_HUMAN |
Herpes simplex infection [ICD-11: 1F00] |
P84022 |
SMAD3_HUMAN |
Kidney fibrosis [ICD-11: GC01] |
Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P27695 |
APEX1_HUMAN |
Retinopathy [ICD-11: 9B71] |
P27695 |
APEX1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P27695 |
APEX1_HUMAN |
Ocular cancer [ICD-11: 2D00-2D07] |
P27695 |
APEX1_HUMAN |
Brain cancer [ICD-11: 2A00] |
P27695 |
APEX1_HUMAN |
Melanoma [ICD-11: 2C30] |
P25779 |
CYSP_TRYCR |
Parasitic worm infestation [ICD-11: 1F90] |
P25779 |
CYSP_TRYCR |
Malaria [ICD-11: 1F40-1F45] |
O75604 |
UBP2_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P04637 |
P53_HUMAN |
Arterial occlusive disease [ICD-11: BD40] |
P04637 |
P53_HUMAN |
Lip/oral cavity/pharynx neoplasm [ICD-11: 2B6E] |
P04637 |
P53_HUMAN |
Metastatic liver/bile duct neoplasm [ICD-11: 2D80] |
P04637 |
P53_HUMAN |
Transplant rejection [ICD-11: NE84] |
P04637 |
P53_HUMAN |
Ovarian dysfunction [ICD-11: 5A80] |
P04637 |
P53_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P04637 |
P53_HUMAN |
Bladder cancer [ICD-11: 2C94] |
P04637 |
P53_HUMAN |
Brain cancer [ICD-11: 2A00] |
P04637 |
P53_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P04637 |
P53_HUMAN |
Esophageal cancer [ICD-11: 2B70] |
P04637 |
P53_HUMAN |
Head and neck cancer [ICD-11: 2D42] |
P04637 |
P53_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P04637 |
P53_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
P04637 |
P53_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
P04637 |
P53_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P04637 |
P53_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04637 |
P53_HUMAN |
Stomach cancer [ICD-11: 2B72] |
P04637 |
P53_HUMAN |
Cervical cancer [ICD-11: 2C77] |
P04637 |
P53_HUMAN |
Endometrial cancer [ICD-11: 2C76] |
P04637 |
P53_HUMAN |
Fallopian tube cancer [ICD-11: 2C74] |
P04637 |
P53_HUMAN |
Liposarcoma [ICD-11: 2B59] |
P04637 |
P53_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P04637 |
P53_HUMAN |
Peritoneal cancer [ICD-11: 2C51] |
P04637 |
P53_HUMAN |
Toxicity [ICD-11: N.A.] |
P04637 |
P53_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04637 |
P53_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P04637 |
P53_HUMAN |
Kidney failure [ICD-11: GB60-GB6Z] |
P04637 |
P53_HUMAN |
Hearing disorder [ICD-11: AB50-AB57] |